Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency

January 4, 2018
At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).
Previous Article
Prometic to present new data on how plasminogen reduces acute lung injury at the american thoracic society’s 2017 international conference
Prometic to present new data on how plasminogen reduces acute lung injury at the american thoracic society’s 2017 international conference

Next Article
Prometic completes the filing of its plasminogen biologics license application (“BLA”) with the U.S. FDA
Prometic completes the filing of its plasminogen biologics license application (“BLA”) with the U.S. FDA